Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients

scientific article

Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1365-2125.1981.TB01851.X
P932PMC publication ID1401743
P698PubMed publication ID7248139
P5875ResearchGate publication ID15951239

P2093author name stringP K Duffner
J J MacKichan
M E Cohen
P2860cites workCSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patientsQ34515320
Salivary levels of anticonvulsants: A practical approach to drug monitoringQ39145895
Drug concentration in salivaQ39212688
The binding of drugs by plasma proteinsQ39973717
Plasma and tissue protein binding of drugs in pharmacokineticsQ40809296
Clinical Pharmacokinetics of CarbamazepineQ40877361
A comparison of phenobarbitone and primidone in the control of seizures in chronic epilepsy [proceedings]Q41045338
Carbamazepine: absorption, distribution, and excretionQ44394933
The Pharmacokinetics of Carbamazepine in Plasma and Saliva of ManQ44584927
Saliva carbamazepine levels in childrenQ55184696
Plasma protein binding of carbamazepineQ66918773
Anticonvulsant Level in Saliva, Serum, and Cerebrospinal FluidQ66956563
Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and salivaQ67274955
Carbamazepine for epilepsy. A controlled prospective evaluationQ67288336
Carbamazepine: biotransformationQ67373029
Distribution and elimination kinetics of carbamazepine in manQ67396517
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple dosesQ67396551
Parotid and whole saliva in the prediction of serum total and free phenytoin concentrationsQ67403367
Kinetics of carbamazepine and its 10,11‐epoxide metabolite in childrenQ67443848
Carbamazepine and its 10,11-epoxide in children and adults with epilepsyQ67549281
Studies on plasma protein binding of carbamazepineQ68929708
Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsyQ69646920
Simultaneous liquid chromatographic analysis for carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva by use of double internal standardizationQ71242227
Physicochemical and Biochemical Aspects of PharmacologyQ72348272
The comparative enzyme-inducing properties of antiepileptic drugs [proceedings]Q95774218
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectcarbamazepinQ410412
P304page(s)31-37
P577publication date1981-07-01
P1433published inBritish Journal of Clinical PharmacologyQ176044
P1476titleSalivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients
P478volume12

Reverse relations

cites work (P2860)
Q50016064A descriptive systematic review of salivary TDM in neonates and infants
Q41819119A simple collection method for saliva in children: potential for home monitoring of carbamazepine therapy
Q40142216Anticonvulsant drugs. An update
Q42094822Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants
Q42531420Carbamazepine 10,11-epoxide in children
Q67888965Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates
Q39738819Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update
Q40959033Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate
Q42531581Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein
Q42251696Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects
Q93645811Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication
Q39754383Free drug concentration monitoring in clinical practice. Rationale and current status
Q69620797High-performance liquid chromatographic determination of carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva following solid-phase sample extraction
Q39074126Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children
Q41763892Progabide-induced changes in carbamazepine metabolism
Q69395064Simultaneous quantitation of salivary carbamazepine, carbamazepine-10,11-epoxide, phenytoin and phenobarbitone by high-performance liquid chromatography
Q34448173The effects of age on carbamazepine pharmacokinetics and adverse effects
Q42873945The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results.
Q33700135Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants
Q35653966Therapeutic drug monitoring in saliva. An update